As many as half of people who develop Alzheimer’s dementia experience the symptom of agitation, which can lead to behaviors like pacing, restlessness, and…
After almost two decades of stagnation, two new drugs for Alzheimer’s have hit the market in the last three years. The approval of Biogen…
Despite decades of study, the underlying cause of Alzheimer’s continues to evade scientists. Because it’s such a mystery, there are only six drugs approved for…
In June, the Food and Drug Administration will decide whether to grant full approval to Biogen and Eisai’s anti-amyloid Alzheimer’s drug Leqembi (generic name…
As Julie Fleming’s father slipped into the later stages of Alzheimer’s dementia, she could only watch as his computer skills and interests faded. “The…
Last April, the Centers for Medicare and Medicaid Services (CMS) decided to limit the coverage of the controversial Alzheimer’s drug Aduhelm and similar drugs…
Eisai and Biogen’s new anti-amyloid drug Leqembi was recently approved through the FDA’s accelerated pathway. Now, it’s on the market with a price tag…
Alzheimer’s disease is a progressive neurodegenerative condition that affects more than one in every nine Americans over the age of 65. Managing its symptoms…
According to drugmaker Eli Lilly, the FDA has rejected the company’s application for the FDA’s “Accelerated Approval” designation for experimental Alzheimer’s drug donanemab. The…
Gordon Van Slyke’s mother and sister both passed away of early onset Alzheimer’s when they were in their early 60s. When he decided to…
I received my diagnosis of early Alzheimer’s in July 2016 through participation in a clinical trial for Biogen’s aducanumab (now known as Aduhelm). Except…
Update: As of July 6, 2023, the drug has full, traditional FDA approval. Today, the Food and Drug Administration approved Leqembi (generic name lecanemab), a…
The United States imposed a blockade against Cuba in 1961, and currently there isn’t much collaboration — or even, much communication — about medical…
The majority of experimental Alzheimer’s drugs are being designed to halt the progression of the disease — a strategy which so far has yielded…
The approval of the controversial anti-amyloid drug Aduhelm last year marked a major milestone for Alzheimer’s research — it became the first new drug…